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Abstract
Background: Despite recently implemented access to care programs, Mexican breast cancer (BC) mortality rates
remain substantially above those in the US. We conducted a survey among Mexican Oncologists to determine
whether practice patterns may be responsible for these differences.
Methods: A web-based survey was sent to 851 oncologists across Mexico using the Vanderbilt University REDCap
database. Analyses of outcomes are reported using exact and binomial confidence bounds and tests.
Results: 138 participants (18.6% of those surveyed) from the National capital and 26 Mexican states, responded.
Respondents reported that 58% of newly diagnosed BC patients present with stage III-IV disease; 63% undergo
mastectomy, 52% axillary lymph node dissection (ALND) and 48% sentinel lymph node biopsy (SLNB). Chemotherapy
is recommended for tumors>1 cm (89%), positive nodes (86.5%), triple-negative (TN) (80%) and HER2 positive
tumors (58%). Trastuzumab is prescribed in 54.3% and 77.5% for HER2< 1 cm and> 1 cm tumors, respectively.
Tamoxifen is indicated for premenopausal hormone receptor (HR) positive tumors in 86.5% of cases and aromatase
inhibitors (AI’s) for postmenopausal in 86%. 24% of physicians reported treatment limitations, due to delayed or
incomplete pathology reports and delayed or limited access to medications.
Conclusions: Even though access to care programs have been recently applied nationwide, women commonly
present with advanced BC, leading to increased rates of mastectomy and ALND. Mexican physicians are dissatisfied
with access to appropriate medical care. Our survey detects specific barriers that may impact BC outcomes in
Mexico and warrant further investigation.
Keywords: Breast cancer, Socioeconomic disparities, Mexico, Access to care, Patterns of care, Survey
Background
Breast cancer (BC) is the leading cancer among women
worldwide [1,2]. In Mexico, BC incidence has been in-
creasing in recent decades with 8,428 cases reported in
2009. This reflects a national incidence of 15 per 100,000
women compared with 76 per 100,000 women in the US,
although figures in Mexico are underreported due to a
lack of a National Cancer Registry [3]. Since 2006 it has
been the leading cause of cancer mortality in Mexican
women, accounting for 14% of all female cancer-related
deaths [4]. While the incidence of BC in Mexico is lower
than the US, the ratio mortality/incidence in Mexico is al-
most the double that in the US (37% vs. 18.7%) [5].
Recent changes in Mexican health care policies have
incorporated programs addressing access to early breast
cancer (EBC) diagnosis and treatment [6]. The implemen-
tation of the Seguro Popular (SP), the Mexican Health In-
surance in 2003, was part of health reform intended to
provide health coverage for the poor and uninsured [7].
SP also includes protection of the poor from “catastrophic
health expenditures”, such as those commonly resulting
from a diagnosis and subsequent treatment of BC [7]. In
2011, the BC protocol for SP included: diagnostic workup
for EBC; local and systemic treatment, such as breast and
axillary surgery (breast conservation surgery/mastectomy
and SLNB/ALND); and, when appropriate, adjuvant radi-
ation therapy, chemotherapy, endocrine therapy (ET) and
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SP program appears to have had a significant impact on
access to BC care, there remains a paucity of data as to
whether the program has yet impacted the incidence and
mortality of BC [10].
The aim of the survey reported here, was to assess pat-
terns of current care among a spectrum of oncologists
currently providing clinical care to newly diagnosed BC
patients in Mexico. Assessment of physician’s decisions
under scenarios of free access to care versus current ac-
cess to care was our means of examining how socioeco-
nomic factors impact patient care.
Methods
A list of oncologists was obtained from the Mexican On-
cology Board [11]. There were a total of 983 oncologists
listed within the Mexican Oncology Board who had an
available email address (including medical oncologists, on-
cologic surgeons, gynecologic oncologists, radiotherapists,
and pediatric oncologists). From the MGH-Avon Inter-
national Breast Cancer Program in Boston, a web-based
survey was sent to 851 oncologists (excluding 132
pediatric oncologists). Non-responders were sent email re-
minders to complete the survey 2, 3 and 7 weeks after
the initial invitation. No incentives were offered to par-
ticipating physicians.
The survey consisted of 35 questions which were di-
vided into sections that addressed: physician demograph-
ics; BC patient demographics and clinical presentation;
details of pathology reports and; patterns of treatment for
patients with EBC (Additional file 1: Figure S1). Questions
addressing systemic therapy could be answered with more
than one option. Anonymous responses were entered dir-
ectly by the physicians into the Research Electronic Data
Capture (REDCap), a secure Vanderbilt University data-
base, for analysis [12]. All responses were tabulated and
analyzed using Stata Statistical Software: Release 12. Con-
fidence bounds on proportions were derived from Chi-
squared or exact distributions depending on sample size.
Exact binomial proportion confidence intervals were used
to compare distribution of responses. The study was ap-
proved by the Partners Human Research Committee and
complied with the Declaration of Helsinki.
Results
Demographics
One hundred and thirty-eight participants answered the
web-survey, representing an 18.6% response rate (Figure 1).
One hundred and six email addresses experienced delivery
failures. Of the 138 responders, 129 (93%) completed the
questionnaire. Two responders reported that they did not
practice medicine in Mexico and were therefore excluded
from our analyses. Table 1 displays the demographics of
survey participants.
Breast cancer diagnosis
The stage of disease at presentation was 42% for Stage
I-II, 44% for stage III and 14% for stage IV. Physicians
reported that tumor size, tumor grade, vascular invasion,
tumor margin status, lymph node analysis, estrogen re-
ceptor (ER 88.4%), progesterone receptor (PR 87.7%),
and HER2 (87.7%) receptor results were standard ele-
ments of pathology reports (Table 2). The physicians
reported that HER2 analysis was performed by either
immunohistochemistry (93.5%) or fluorescent in situ
hybridization (59.4%). Of the physicians that routinely
tested for HER2, 48% reported that testing was done in
their local hospital, while 49% reported that testing was
performed in a central regional lab. Four percent of phy-
sicians reported that HER2 was not routinely analyzed
in their practice.
Patterns of local therapy
Physicians reported mastectomy rates of 63% and lump-
ectomy rates of 37% in localized breast cancer patients.
In women without palpable lymph nodes, physicians re-
ported SLNB and ALND rates of 48% and 52% respect-
ively. Ninety-four percent of physicians reported that
adjuvant radiotherapy is available. Of those, 92.1% re-
ported that patients routinely receive daily-fractionated
radiotherapy for duration of 5–6 weeks regardless of the
type of surgery or clinical stage.
Patterns of systemic therapy
Physicians reported that neoadjuvant therapy is recom-
mended in 88.4% of their patients that present with stage
III, 27.8% in patients with stage II, and 4.7% of patients
with stage I. An average time interval of 3–12 weeks
851 e-mails sent
106 failures
4 requested removal
741 invitation emails sent
138 participants answered
18.6% participation rate
Figure 1 Flow of participants. 851 members of the Mexican
Oncology Board were invited to participate in the online survey.
106 email addresses experienced delivery failures, and 4 individuals
requested removal from further survey invitations. Subsequently,
741 invitation emails were sent, and 138 participants answered
the survey.
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was reported by 86.6% of the physicians. Others reported
time intervals of less than 3 weeks (11.9%) and greater
than 12 weeks (1.5%).
Management of hormone receptor positive breast cancer
When treating patients with low risk HR +BC (defined
by HER2 negative, less than 1 cm tumors and negative
lymph nodes), 65% of physicians recommend only ET,
26.9% recommend ETand chemotherapy,7.1% only chemo-
therapy and <1% ET and Oncotype assessment (Figure 2).
The most commonly prescribed regimen is anthracy-
c l i n ec h e m o t h e r a p yi n7 3 . 8 % ,f o l l o w e db yt a x a n ei n
35.7%, and anthracycline-taxane regimens in 32.2%.
When treating patients with high risk HR+BC (defined
by HER2 negative, greater than 1 cm tumors, positive
lymph nodes), 52% of physicians recommend combination
ET and chemotherapy and 48% recommend chemother-
apy only (Figure 2). The most commonly prescribed
chemotherapy is anthracycline-taxane (85.2%), followed
by anthracycline (19.3%), taxane (14.7%), taxane-platinum
(<1%), gemcitabine (<1%) and bevacizumab (<1%).
The patterns of ET prescribed for premenopausal
women with HR+tumors are: tamoxifen (55.5%), tam-
oxifen and ovarian suppression (OS) (19%), AI’so n l y
(14.2%), combination of tamoxifen, OS, and AI’s( 1 1 . 9 % ) ,
AI’s and OS (4.7%), and OS only (3.9%). For postmeno-
pausal women, the most common ET prescribed was AI’s
only in 42.1%, followed by tamoxifen and AI’si n3 8 . 2 % ,
tamoxifen only in 14%, OS, tamoxifen, and AI’s( 5 . 4 % )a n d
fulvestrant (<1%). The average duration of therapy pre-
scribed in premenopausal and postmenopausal women for
tamoxifen was 3.9 years in both groups, and for AI’s1 . 5
and 4.3 years, respectively.
Table 1 Demographic characteristics of survey
participants
Characteristics of physicians surveyed Number (Percentage)
Gender
Male 79 (58%)
Female 57 (42%)
Age
<40 years 59 (43%)
40-65 years 74 (54%)
>65 years 3 (2%)
Years since Medical Graduation
1-10 56 (41%)
> 10 80 (59%)
Specialty
Medical Oncology 43 (32%)
Surgical Oncology 79 (58%)
Breast Surgeon 7 (5%)
Other 7 (5%)
Location of Primary Clinical Practice
Academic medical center 36 (26.9%)
Public hospital/clinic 64 (47.8%)
Philanthropic hospital/clinic 2 (1.5%)
Private hospital/clinic 27 (20.1%)
Other 5 (3.7%)
Geographic Area of Practice
Urban Center 130 (95.6%)
Suburban 5 (3.7%)
Rural 1 (0.7%)
Regional Distribution
Northern Mexico 32 (24%)
Central Mexico 83 (62%)
Southern Mexico 18 (14%)
Form of Patient Payment (Estimates)
Out of Pocket (OOP) 20%
Private Insuranc 20%
Public Insurance 51%
Not Insured and Not OOP 8%
Other 1%
Table 2 Characteristics available on pathology reports
Pathologic characteristics Percentage
n =136
Tumor size 96.4
Tumor grade 97.8
Presence/absence of vascular invasion 94.2
Margins 93.5
Lymph node analysis 97.1
Estrogen receptor 88.4
Progesterone receptor 87.7
HER2/neu 87.7
67%
30%
0%
10%
20%
30%
40%
50%
60%
70%
80%
T<1cm, Node (-) T>1cm, Node (+)
C
h
e
m
o
t
h
e
r
a
p
y
Figure 2 Patterns of chemotherapy for ER+disease. 30% of
physicians recommended chemotherapy for patients with ER+
tumors of less than 1 cm in size and negative nodes, while 67% of
physicians recommended chemotherapy for patients with tumors
greater than 1 cm in size and positive nodes.
Chavarri-Guerra et al. BMC Cancer 2014, 14:658 Page 3 of 8
http://www.biomedcentral.com/1471-2407/14/658Management of triple negative breast cancer
With respect to TNBC, with tumors less than 1 cm and
negative lymph nodes, 30.2% recommend no adjuvant
therapy, 37.3% recommend anthracycline-taxane chemo-
therapy, 24.6% anthracycline therapy, and 5.6% taxane
chemotherapy (Figure 3).
For patients with TNBC with tumors greater than 1 cm
and negative lymph nodes, 3.2% of physicians recommend
no adjuvant therapy, 64% recommend anthracycline-taxane
chemotherapy, 22.4% anthracycline therapy, and 8% tax-
ane treatment.
Management of HER2-positive (HER2 +) breast cancer
Physicians treating patients with HER2+ and HR+tumors
that are less than 1 cm with negative lymph nodes recom-
mend ET (79%), trastuzumab (54.3%), and chemotherapy
(36.2%) (Figure 4).
For patients with HER2+ and HR negative tumors that
are greater than 1 cm with positive lymph nodes, 13% of
physicians recommend ET, 77.5% trastuzumab, and 81.2%
chemotherapy (Figure 4).
Forty-eight percent of the physicians surveyed reported
that in the last year there were instances where they
recommended adjuvant trastuzumab to a patient that ul-
timately did not receive it. They estimated that non-
receipt of trastuzumab occurs in 14.4% of their cases. The
most commonly reported reasons for not receiving trastu-
zumab were: lack of financial coverage for trastuzumab
under public health care (26.8%), high out-of-pocket cost
(31.2%), and patient co-morbidities or toxicity concerns
(10.9%). Other reasons, such as patient refusal (6.5%), lack
of coverage for trastuzumab under private health care
(8%), referral to a clinical trial (0.7%), alternative opinion
of another practitioner (4.3%), and inability to make the
trips and visits necessary for treatment (2.9%) were also
cited as reasons for not receiving trastuzumab.
Quality of breast cancer care
Twenty-five percent of physicians changed their treat-
ment recommendations in at least one of the clinical
scenarios if offered free access to any medication (95%
C I ,0 . 1 6t o0 . 3 7 ) .T h r o u g h o u tt h i ss e r i e so fq u e s t i o n s ,
the scenario of free access to treatment led 68% of phy-
sicians to change their decision once, 20% twice, and
12% three times.
With free access to therapy, physicians changed their
recommendations most frequently on questions regard-
ing ET for HR +disease (95% CI, 0.04 to 0.16), chemo-
therapy for TN disease (95% CI, 0.03 to 0.14), and
trastuzumab for HER2+ disease (95% CI, 0.05 to 0.15).
A substantial number of physicians reported that they
were unable to provide the best treatments for their pa-
tients (23.8%). This was attributed to delays in pathology
reports (43.3%), omission of important prognostic and pre-
dictive information on pathology reports (46.7%), restric-
tions for prescribing standard chemotherapy (56.7%), delay
in receipt of chemotherapy after prescription (43.3%), limi-
tations in prescribing standard ET (40%), restrictions in
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Figure 3 Patterns of chemotherapy for TN disease. 67% of
physicians recommended chemotherapy for patients with TN
tumors of less than 1 cm in size, while 94% of physicians
recommended chemotherapy for patients with TN tumors greater
than 1 cm in size.
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Figure 4 Patterns of therapy for HER2+ disease. For patients with tumors that are HER2+, ER+, less than 1 cm in size and node negative, 54%
of physicians recommended trastuzumab, 36% recommended chemotherapy and 79% recommended endocrine therapy. For patients’ tumors
that are HER2+, ER-, greater than 1 cm in size, and node negative, 78% of physicians recommended trastuzumab, 81% recommended chemotherapy,
and 13% recommended endocrine therapy. Participants could select multiple therapy options to describe their treatment of HER2+ patients.
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high workload (40%).
Access to clinical trials
With respect to clinical trials, 47.2% of physicians report
that there are BC clinical trials that are actively enrolling
patients at or near their primary practice. Of the physi-
cians who report having active clinical trials at or near
their primary practice, 68.3% indicated that they regu-
larly recommend their patients for trial enrollment.
Discussion
The goal of our survey was to ascertain patterns of prac-
tice in Mexico from clinical oncologists in an attempt to
obtain treating physicians’ diagnostic and treatment tools
for managing BC. These answers can help derive potential
causes of high Mexican BC mortality rates and suggest
ways of improving the system deficiencies. Our survey
was also conducted in a period post-implementation of
the SP, a health care reform in Mexico aspiring to bring
universal health care to the population.
We acknowledge that this study had several limitations.
First, the response rate was low (18.6%), which might not
be the most accurate representation of Mexican oncolo-
gists. However, we found this group to be geographically
distributed in a statistically comparable way to the overall
geographic distribution of physicians practicing within the
Mexican Society of Oncology (p=0.652) [11]. The phy-
sicians we surveyed likely represented a typical cross
section of treating oncologists because they come from a
spectrum of private and public health care systems as well
as urban and diverse provincial centers. Importantly, in
the subgroup who did respond, we found substantive con-
cern about the impact of socioeconomic barriers on access
to care and physician decision-making. The second limita-
tion of our survey was its web-based platform, making it
inaccessible to physicians without Internet access, which
may have resulted in failure to capture the problems that
remote community physicians face. Third, we are aware of
a non-response bias, which has been apparent by the fact
that the majority of surveyed oncologist reported to have
radiotherapy services access. However it is well recognized
that radiotherapy is not accessible in several regions of the
country [9]. Therefore, we believe the major reason for
large number of non-responders to our survey was limited
access to the Internet, which mainly represent the oncolo-
gists from less specialized centers and underdeveloped
areas in the country.
If anything our survey results may understate the
discrepancies seen in Mexico in comparison to western
countries. It is thus unwise to make definitive conclusions
about patterns of breast cancer care in all of Mexico from
our survey results, although the true situation is likely
to be worse than our results suggest due to under
representation of physicians in underdeveloped and disad-
vantaged areas of the country. We plan a revised survey in
the future using this report as our first benchmark.
Despite the implementation of SP and other programs
intended to increase early detection, surveyed physicians
continue to see newly diagnosed patients presenting with
late stage BC [13,14], and our survey results appear to
affirm that as in other low- and middle-income coun-
tries, mortality rates in Mexico are largely driven by late,
advanced stage of disease at presentation. Specifically
surveyed physicians reported that the majority of their
newly diagnosed patients present with stage III or IV
disease (58%) which is in sharp contrast to the United
States, where only 5-12% of white women and 16-20% of
Hispanic women living in the US, present with late stage
disease at clinical presentation of BC [15,16].
Closer scrutiny of the clinical pathways addressed in
this survey is merited. In terms of early detection, low
participation in screening programs persists despite im-
plementation of early detection programs. This is prob-
ably aggravated by socio-cultural factors that foster
delayed times to diagnosis and limited access to existing
specialized centers, which has been exemplified by a
survey conducted at the US-Mexico border where Mexican
women living in Mexico were less likely to have a screen-
ing mammogram than Latinas living in the US [5,17,18].
Future policies must incorporate methods to improve early
detection focusing on access to care and addressing psy-
chosocial factors that lead women to seek care at late
stages of the disease, such as cultural barriers, lack of
BC awareness in the general population as well as by
primary health care providers, and in many areas where
there are persistent deficiencies in mammographic screen-
ing programs [19].
Our survey found that rates of total mastectomy (63%)
and ALND (52%) are approximately double those seen
in the US (33% and 36%, respectively). This in part prob-
ably reflects more advanced stage at diagnosis, which is
more commonly seen in Mexico and often precludes
conservative surgery [9,20,21]. In terms of local disease
control through radiation therapy, although 94% of phy-
sicians reported availability of adjuvant radiotherapy for
their patients, the high rates of mastectomy and ALND
in patients without palpable nodes may partially be due
to the known lack of available and centralized radiation
oncology specialists in Mexico, as well as the costs asso-
ciated with SLNB procedures [9].
In terms of adequate, available pathology reporting,
the crucial component of clinical decision-making, the
majority (88%) of surveyed physicians report receiving
pathology reports that meet international recommenda-
tions. However, this rate of adequacy is still lower than
that reported in US (98.5%) [16], and contradictory with
the statement above, nearly a quarter of physicians claim
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their patients, mainly due to delays in pathology reports,
and omission of important prognostic and predictive
information. These delays and omissions may have a
significant impact on the physician’s ability to facilitate
appropriate treatments in a timely manner. We and
others, have shown that pathology reporting errors are a
commonly encountered problem worldwide, exemplified
by the 20% discrepancy in results of HER2 biomarker over-
expression assessment between central and local laborator-
ies, which can lead to very costly under- or overtreatment
of women with HER2+BC [22]. Quality control programs
within BC pathology laboratories urgently need to be
addressed in Mexico, as well as internationally.
In terms of adjuvant ET, a key measure in improving
mortality risk is to provide appropriate treatment for
young premenopausal women, who are disproportion-
ately represented in a young population such as Mexico
[14]. The most common ET for women with HR+tumors
is tamoxifen without OS for premenopausal women and
AI’s for postmenopausal women, comparable to standard
practice in the US. Worryingly however, some 14% of phy-
sicians in our survey recommended AI’s as mono-therapy
for premenopausal women, which is known to be ineffect-
ive, may cause unwanted pregnancies, and even com-
promise outcome results [23]. Furthermore, five percent
of physicians also recommended costly OS for postmeno-
pausal women, despite its complete ineffectiveness. Urgent
education programs are needed to avoid the increased
costs and morbidities associated with these improper
practices [24]. Adjuvant chemotherapies are usually rec-
ommended by the physicians we surveyed for high-risk
patients with larger tumors, node positive tumors, and
TN and HER2+ tumors. These are comparable to adju-
vant chemotherapy practice patterns in the US reported
in 2002, where nearly 80% of physicians prescribed
chemotherapy for node positive disease [25]. Again, it is
troubling that one quarter of the physicians we surveyed
reported concerns about being able to provide the best
treatment for their patients. More than half attributed
this failure to restricted availability of the optimal
chemotherapy choice.
The accelerating pace of scientific development in BC
has been increasing during the last decades, which needs
evaluation through clinical trials. Our results indicate
that Mexican oncologists are well sensitized to refer pa-
tients to clinical trials enrollment and comparable to US
rate (Mexican surveyed oncologist 68% vs. US oncologist
56.7-71%) [26,27].
Results of our survey highlight the important problem
of ongoing financial barriers to optimal clinical care of
BC patients in Mexico. This problem is exemplified by
the result that 25% of the physicians we surveyed chan-
ged their treatment recommendations when presented
with a hypothetical treatment scenario involving free ac-
cess to medications. While cost constraints are a universal
consideration in cancer care, physicians in Mexico are
forced to weigh difficult financial decisions when consid-
ering how best to treat their patients. These restraints fre-
quently end up hindering their ability to deliver standard,
guideline-based care. A specific example of this is treat-
ment decisions in HER2+ BC. Although a majority of phy-
sicians report testing patients for tumor HER2 positivity,
48.4% stated that there are instances when they have rec-
ommended adjuvant trastuzumab to a patient and that
the patient has not been able to receive it. The most com-
mon reasons cited for this is lack of coverage under public
health care and high out-of-pocket cost. As failure to treat
this specific sub-type of BC will contribute to dispropor-
tionately higher mortality rates, this finding in our survey
is particularly troubling and highlights that despite the im-
plementation of SP, cancer care is still not optimal.
Our survey highlights significant patterns of practice
among current oncologists which are likely to have an
adverse impact on patients’ outcomes. The patterns of
care have been show to be amenable to change. Imple-
mentation and monitoring of practice guidelines within
Mexico, implementation of tumor board educational
telemedicine and other interventions are some examples
of measures that may be helpful.
Conclusions
The SP health system reform in Mexico is widely recog-
nized as both an outstanding and challenging strategy
designed to ameliorate a previously inefficient health
care system. However, health systems often need to be
modified and tailored over time in response to detection
of nation’s specific health care needs [28].
Currently, with the implementation of the SP and the
social security health care services, “virtually” every
woman in Mexico should have warrantee access to BC
diagnosis and treatment. However, distribution of spe-
cialized centers and physicians, as well as socio-cultural
factors, might contribute to the persistence of poor ac-
cess to timely, adequate and complete BC diagnosis and
treatment for certain populations identified by this sur-
vey. This potential barrier to care should be investigated
further to grasp the extent of this issue and also must be
acknowledged by health authorities. Our survey has
highlighted an urgent need for improving education
among physicians in order to promote judicious use of
existing resources. The intention of this survey is to
highlight opportunistic areas for improvement within
the BC care chain, which are relevant not only to the
oncology authorities, but also could serve as a model for
addressing access issues in the treatment of other non-
communicable diseases in Mexico and other developing
countries.
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